Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral capsule
intravenous injection |
| gptkbp:approves |
gptkb:1983
gptkb:FDA gptkb:EMA |
| gptkbp:associated_with |
increased risk of cancer
increased risk of infections |
| gptkbp:available_in |
oral form
injectable form |
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
gptkb:Neoral
gptkb:Sandimmune |
| gptkbp:chemical_formula |
C62 H111 N11 O12
|
| gptkbp:class |
cyclic peptide
|
| gptkbp:contraindication |
active infections
malignancies hypersensitivity to cyclosporine |
| gptkbp:developed_by |
gptkb:Sandoz
gptkb:yeast |
| gptkbp:discovered_by |
1970s
|
| gptkbp:dissolved |
lipophilic
|
| https://www.w3.org/2000/01/rdf-schema#label |
cyclosporine A
|
| gptkbp:interacts_with |
gptkb:fruit
certain antibiotics antifungal medications |
| gptkbp:is_analyzed_in |
treatment of psoriasis
treatment of multiple sclerosis new immunosuppressive therapies treatment of Crohn's disease treatment of lupus |
| gptkbp:is_monitored_by |
kidney function
liver function blood levels |
| gptkbp:lifespan |
5 to 18 hours
|
| gptkbp:mechanism_of_action |
inhibits T-cell activation
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:produced_by |
gptkb:Novartis
|
| gptkbp:side_effect |
hypertension
hyperlipidemia nephrotoxicity |
| gptkbp:suitable_for |
pregnancy
breastfeeding severe liver disease severe kidney disease |
| gptkbp:used_for |
organ transplantation
autoimmune diseases |
| gptkbp:used_in |
rheumatoid arthritis treatment
heart transplantation kidney transplantation liver transplantation psoriasis treatment uveitis treatment |
| gptkbp:bfsParent |
gptkb:Restasis
|
| gptkbp:bfsLayer |
6
|